现实世界中的结核病疫苗：结核病流行地区的临床试验

Real world TB vaccines: clinical trials in TB-endemic regions.

作者信息

Doherty T Mark

机构信息

Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark.

出版信息

Vaccine. 2005 Mar 18;23(17-18):2109-14. doi: 10.1016/j.vaccine.2005.01.060.

DOI:10.1016/j.vaccine.2005.01.060

PMID:15755580

Abstract

The first 4 years of the 21st century have been an exciting time for tuberculosis (TB) research. After more than a half-century, the first new vaccines for TB are beginning to enter human clinical trials. Based on advances in proteomics and genomics, new vaccine candidates are filling the preclinical pipeline and our understanding of the natural history of M. tuberculosis infection is expanding rapidly. This review summarizes the developing consensus on the BCG vaccine and its limitations and discusses clinical trials of some of the new vaccines intended to supplement or replace it.

摘要

21世纪的头4年对于结核病（TB）研究来说是令人兴奋的时期。在半个多世纪之后，首批新型结核病疫苗开始进入人体临床试验。基于蛋白质组学和基因组学的进展，新的候选疫苗正源源不断地进入临床前研发阶段，并且我们对结核分枝杆菌感染自然史的理解也在迅速扩展。本综述总结了关于卡介苗（BCG）疫苗及其局限性的逐渐形成的共识，并讨论了一些旨在补充或替代卡介苗的新型疫苗的临床试验情况。